Effect of canagliflozin in non-diabetic obese patients with albuminuria: A  randomized, double-blind, placebo-controlled trial

CONCLUSION: Canagliflozin 100 mg daily was well tolerated but did not significantly reduce UACR in non-diabetic obese patients with microalbuminuria. However, a significant temporary decline in eGFR might reflect a subtle reduction in glomerular hyperfiltration.PMID:37675488 | DOI:10.5414/CN111143

Source: Clinical Nephrology - September 7, 2023 Category: Urology & Nephrology Authors: Primploy Greeviroj Pongpratch Puapatanakul Jeerath Phannajit Kullaya Takkavatakarn Wonngarm Kittanamongkolchai Patchaya Boonchaya-Anant Pisut Katavetin Kearkiat Praditpornsilpa Somchai Eiam-Ong Paweena Susantitaphong Source Type: research